Aim To compare the effect of different administration of rosuvastatin on levels of serum inflammation factors in patients with acute coronary syndrome （ACS）. Methods 86 patients diagnosed as ACS were chosen and divided into two groups, research group （43 cases, administered rosuvastatin 40 mg at draught and oral intake of rosuvastatin 20 mg, qn ） and control group （43 cases, received oral intake of rosuvastatin 10 mg, qn）, according to the dosage regimen of rosuvastatin. All patients of two groups received 6 months therapy. The levels of high sensitivity C reactive protein （hs-CRP）, thromboxane （TXβ₂） and homocysteine （Hcy） were compared between two groups, and the levels of total cholesterol（TC）, high density lipoprotein （HDL）, low density lipoprotein （LDL） and oxidized LDL （ox-LDL） were also compared between two groups. By following-up for one year, the incidence rates of major cardiovascular events （MACE） were compared between two groups and the relativities between hs-CRP, TXβ₂, Hcy and the incidence rate of MACE were analyzed. Results Compared with control group, the levels of hs-CRP, TXβ₂ and Hcy were significantly decreased （P<0.05） as well as the the level of TC, LDL and ox-LDL in research group （P<0.05）, but the level of HDL in research group was higher （P0.029）. The incidence rates of MACE in research group was lower than in control group （P0.038）. The relativities between hs-CRP, TXβ₂, Hcy and the incidence rate of MACE were positive.Conclusion The administration of high-dose rosuvastatin could significantly reduce the levels of serum inflammation factors and improve the prognosis in patients with ACS.